Impact of Whole-Body 18F-FDG PET on Staging and Managing Patients with Breast Cancer: The Referring Physician’s Perspective

FDG PET has emerged as an important clinical imaging modality for diagnosing and staging cancer. However, the impact of FDG PET on staging and managing patients with breast cancer from the referring physician’s point of view is unknown. Methods: The referring physicians of 160 breast cancer patients received standardized questionnaires inquiring if and how PET findings altered their patient’s stage and their clinical management de-cisions. Management changes were classified as intermodality if the change was from one modality to another (e.g., medical to surgical, surgical to radiation, medical to no treatment, and vice versa) or as intramodality if the change was within the same modality (e.g., altered medical or radiotherapy approach). Re-sults: Fifty of the 160 surveys were completed (31 % response rate). PET changed the clinical stage in 36 % of patients (28% upstaged, 8 % downstaged) and resulted in intermodalit